Literature DB >> 19054825

Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative.

L Gossec1, M Dougados, N Rincheval, A Balanescu, D T Boumpas, S Canadelo, L Carmona, J-P Daurès, M de Wit, B A C Dijkmans, M Englbrecht, Z Gunendi, T Heiberg, J R Kirwan, E M Mola, M Matucci-Cerinic, K Otsa, G Schett, T Sokka, G A Wells, G J Aanerud, A Celano, A Dudkin, C Hernandez, K Koutsogianni, F N Akca, A-M Petre, P Richards, M Scholte-Voshaar, G Von Krause, T K Kvien.   

Abstract

BACKGROUND: Current response criteria in rheumatoid arthritis (RA) usually assess only three patient-reported outcomes (PROs): pain, functional disability and patient global assessment. Other important PROs such as fatigue are not included.
OBJECTIVE: To elaborate a patient-derived composite response index for use in clinical trials in RA, the RA Impact of Disease (RAID) score.
METHODS: Ten patients identified 17 domains or areas of health relevant for inclusion in the score, then 96 patients (10 per country in 10 European countries) ranked these domains in order of decreasing importance. The seven most important domains were selected. Instruments were chosen for each domain after extensive literature research of psychometric properties and expert opinion. The relative weight of each of the domains was obtained from 505 patients who were asked to "distribute 100 points" among the seven domains. The average ranks of importance of these domains were then computed.
RESULTS: The RAID score includes seven domains with the following relative weights: pain (21%), functional disability (16%), fatigue (15%), emotional well-being (12%), sleep (12%), coping (12%) and physical well-being (12%). Weights were similar across countries and across patient and disease characteristics. Proposed instruments include the Health Assessment Questionnaire and numerical ratings scales.
CONCLUSION: The preliminary RAID score is a patient-derived weighted score to assess the impact of RA. An ongoing study will allow the final choice of questionnaires and assessment of validity. This score can be used in clinical trials as a new composite index that captures information relevant to patients.

Entities:  

Mesh:

Year:  2008        PMID: 19054825     DOI: 10.1136/ard.2008.100271

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  66 in total

Review 1.  [Self-monitoring in inflammatory rheumatic diseases].

Authors:  C Kampling; G Chehab; M Schneider; J G Richter
Journal:  Z Rheumatol       Date:  2014-10       Impact factor: 1.372

Review 2.  Treating Fatigue in Rheumatoid Arthritis: Does Patient Age Matter?

Authors:  Till Uhlig; Sella A Provan
Journal:  Drugs Aging       Date:  2018-10       Impact factor: 3.923

Review 3.  Measurement properties of rheumatoid arthritis-specific quality-of-life questionnaires: systematic review of the literature.

Authors:  Jiyeon Lee; Soo Hyun Kim; Seung Hei Moon; Eun-Hyun Lee
Journal:  Qual Life Res       Date:  2014-05-21       Impact factor: 4.147

4.  [Depression as a systemic feature of rheumatoid arthritis].

Authors:  M Englbrecht; J Wendler; R Alten
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

Review 5.  Patient reported outcomes in rheumatoid arthritis clinical trials.

Authors:  Ana-Maria Orbai; Clifton O Bingham
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

6.  Functional and Radiographic Outcomes of the Sauvé-Kapandji and Darrach Procedures in Rheumatoid Arthritis.

Authors:  Hannah M Carl; Scott D Lifchez
Journal:  J Hand Microsurg       Date:  2018-09-27

7.  Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes.

Authors:  T Sanderson; M Morris; M Calnan; P Richards; S Hewlett
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

8.  OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Authors:  Joanna C Robson; Gunnar Tomasson; Nataliya Milman; Sue Ashdown; Annelies Boonen; George C Casey; Peter F Cronholm; David Cuthbertson; Jill Dawson; Haner Direskeneli; Ebony Easley; Tanaz A Kermani; John T Farrar; Don Gebhart; Georgia Lanier; Raashid A Luqmani; Alfred Mahr; Carol A McAlear; Jacqueline Peck; Beverley Shea; Judy A Shea; Antoine G Sreih; Peter S Tugwell; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

9.  Health Care Visits as a Risk Factor for Tuberculosis in Taiwan: A Population-Based Case-Control Study.

Authors:  Sung-Ching Pan; Chien-Chou Chen; Yi-Ting Chiang; Hsing-Yi Chang; Chi-Tai Fang; Hsien-Ho Lin
Journal:  Am J Public Health       Date:  2016-05-19       Impact factor: 9.308

Review 10.  Patient-reported outcomes in core domain sets for rheumatic diseases.

Authors:  Lilian H D van Tuyl; Maarten Boers
Journal:  Nat Rev Rheumatol       Date:  2015-09-01       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.